Loading stock data…
ORKA
$65.68+1.09 (+1.69%)
Market ClosedLast close May 11
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Oruka Therapeutics, Inc. in the Healthcare sector is trading at $65.68. The stock is currently 28% below its 52-week high of $91.00, remaining 103.8% above its 200-day moving average. Technical signals show neutral RSI of 46 and bearish MACD signal, explaining why ORKA maintains its current momentum and trend strength. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 46) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$65.68
Potential Upside
5%
Whystock Fair Value$68.96
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus12 analysts
Mean target$142.17+116.5%
Range$100.00 – $200.00
Fundamentals
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that t...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$3.50B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-22.48%
Volume
Today's trading volume
934,996
Recent News
A Tiny Biotech Just Beat AbbVie's $17 Billion Drug. Should Investors Be Worried?
It's not the news that AbbVie needed, given the challenging year it is having.
H.C. Wainwright Bullish on Halozyme Therapeutics, Inc. (HALO) Commercial Revenue Outlook
We recently compiled a list of the 10 Best Cancer Stocks to Buy for the Long Term. Halozyme Therapeutics, Inc. is one of the best cancer stocks to invest in. TheFly reported on April 29 that H.C. Wainwright increased its price objective for HALO to $95 from $90 and reiterated its Buy recommendation on the […]
Leerink Partners Lifts PT on Oruka Therapeutics, Inc. (ORKA)
Oruka Therapeutics, Inc. (NASDAQ:ORKA) is one of the best performing healthcare stocks so far in 2026. Leerink Partners lifted the price target on Oruka Therapeutics, Inc. (NASDAQ:ORKA) to $120 from $109 on April 30, reaffirming an Outperform rating on the shares. In a separate development, Oruka Therapeutics, Inc. (NASDAQ:ORKA) announced on April 27 positive interim […]
Why Oruka Therapeutics (ORKA) Is Down 6.3% After $700 Million Follow-On Amid Psoriasis Breakthrough
In late April 2026, Oruka Therapeutics completed a US$700.35 million follow-on offering of 9,660,000 common shares at US$72.50 each, shortly after reporting positive interim Phase 2a results for its psoriasis candidate ORKA-001. The company also entered an exclusive global collaboration and license agreement with Halozyme’s Hypercon technology, aiming to refine ORKA-001’s delivery profile for chronic skin conditions such as psoriasis. We’ll examine how the Halozyme collaboration and...
Halozyme and Oruka sign agreement for Hypercon technology
The collaboration targets the development of ORKA-001 and allows for expansion to one additional target.